IV Spanish Consensus Conference on Helicobacter pylori infection treatment

Gisbert, Javier P.; Molina–Infante, Javier; Amador, Javier; Bermejo, Fernando; Bujanda, Luís; Calvet, Xavier; Castro‐Fernández, Manuel; Cuadrado‐Lavín, Antonio; Elizalde, J. Ignasi; Gené, Emili; Gomollón, Fernando; Lanas, Fernando; Argila, Carlos Martín de; Mearin, Fermı́n; Montoro, Miguel; Pérez-Aísa, Ángeles; Pérez-Trallero, Emilio; McNicholl, Adrián G.

doi:10.1016/j.gastre.2016.11.007

Cited by 54 publications

(102 citation statements)

References 175 publications

Supporting

Mentioning

100

Contrasting

Order By: Relevance

“…This study revealed that serum vitamin B 12 levels are significantly lower in infected patients than in uninfected patients and that H. pylori eradication significantly increases vitamin B 12 levels [128]. This has enabled the inclusion of vitamin B 12 deficiency in the consensus and management guides of H. pylori infection as an indication to evaluate and eradicate the bacteria [27,29].…”

Section: Management Of Vitamin B 12 Deficiency In the Post-helicobactmentioning

confidence: 91%

“…Until September 2015, the scientific community has recognized three hematologic diseases as extragastric manifestations of H. pylori infection: iron deficiency [21][22][23][24][25][26][27][28][29][30], vitamin B 12 deficiency [27,29], and immune thrombocytopenia (ITP) [21,[23][24][25][26][27][28][29][30][31]. These will be carefully analyzed in the following subsections.…”

Section: Hematological Diseases Recognized As Related To H Pylorimentioning

confidence: 99%

“…The first decade of the twenty-first century provided most of the studies that currently support the five meta-analyses associating H. pylori infection with iron deficiency and the resolution of disease following infection eradication [46][47][48][49][50] in children [51][52][53][54][55][56][57][58][59][60], in pubescent males and females [61,62], in prepubertal girls [63], in adult men and women [40,45,[64][65][66][67][68][69][70][71][72][73][74][75], in seniors [76], in pregnant women [63], and in non-pregnant women [77]. In addition, these studies have provided scientific support to the different consensus and guidelines for incorporating iron deficiency into the medical management of H. pylori infection as an extragastric manifestation and indication for eradication [21][22][23][24][25][26][27][28][29][30].…”

Section: H Pylori and Iron Deficiencymentioning

confidence: 99%

“…Thanks to over 250 referenced studies in the literature aiming to clarify different aspects of the association between H. pylori and the development of iron deficiency, five meta-analyses are now available that demonstrate the impact of infection on the development of iron deficiency and that infection eradication improves hematological parameters and ferrokinetics [46][47][48][49][50]. These analyses have enabled the scientific community, particularly the consensus and management guides, to incorporate iron deficiency of unexplained origin as an indication to evaluate and eradicate H. pylori infection, when present, in adults as well as children [21][22][23][24][25][26][27][28][29][30].…”

Section: Management Of Iron Deficiency In the Post-helicobacter Eramentioning

confidence: 99%

“…The 40 series of cases previously discussed, a meta-analysis [211] and two systematic reviews [212,213] demonstrated the burden of H. pylori infection on the development of ITP and that eradicating the infection improves the platelet count in more than 50% of the adult patients with chronic ITP [211][212][213]. This has permitted the scientific community, in particular the consensus and management guides of H. pylori infection, to include ITP as an indication for evaluating and eradicating the infection prior to proceeding with other traditional interventions in both adults and children [21,[23][24][25][26][27][28][29][30].…”

Section: Management Of Itp In the Post-helicobacter Eramentioning

confidence: 99%

See 4 more Smart Citations

Helicobacter pylori and Hematologic Diseases

Campuzano-Maya¹

2016

Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview

View full text Add to dashboard Cite

Helicobacter pylori infection is the most common infection of the human species, with developing countries displaying a marked disadvantage in contrast to developing countries. While H. pylori infection is asymptomatic in most infected individuals, it is intimately related to malignant diseases of the stomach, such as gastric cancer and gastric MALT lymphoma, as well as benign diseases, for example chronic gastritis and duodenal and gastric peptic ulcers. Since the discovery that gastric mucosa could be colonized by bacteria, evidence of greater than 50 extragastric manifestations has been reported, linking H. pylori infection and the development of diseases associated with cardiology, dermatology, endocrinology, obstetrics and gynecology, hematology, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology, and pediatrics. This chapter presents the extragastric manifestations of H. pylori infection expressed through hematologic diseases; particularly those included in the international consensus, and discusses guidelines for the management of H. pylori infection, such as iron deficiency, vitamin B 12 (cobalamin) deficiency, and immune thrombocytopenia. Other manifestations reviewed include immune neutropenia, antiphospholipid syndrome, and plasma cell dyscrasias, such us monoclonal gammopathy of undetermined significance, multiple myeloma, and Henoch-Schönlein purpura.

show abstract

Section: Management Of Vitamin B 12 Deficiency In the Post-helicobactmentioning

confidence: 91%

Section: Hematological Diseases Recognized As Related To H Pylorimentioning

confidence: 99%

Section: H Pylori and Iron Deficiencymentioning

confidence: 99%

Section: Management Of Iron Deficiency In the Post-helicobacter Eramentioning

confidence: 99%

Section: Management Of Itp In the Post-helicobacter Eramentioning

confidence: 99%

See 3 more Smart Citations

Helicobacter pylori and Hematologic Diseases

Campuzano-Maya¹

2016

Extradigestive Manifestations of Helicobacter Pylori Infection - An Overview

View full text Add to dashboard Cite

show abstract

Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients

2019

Self Cite

View full text Add to dashboard Cite

Background: Manychangeshavebeenmadetotheguidelinesonrescuetreatmentsfor Helicobacter pylori infection due to their poor effectiveness in clinical practice.Objective: To evaluate the use and effectiveness of different empirical rescue therapies for H. pylori infection in a specialised consultation unit over 18 years. Methods:Design: analysis of a systematic, prospective, single-centre data record.Patients: consecutive patients in whom at least one H. pylori eradication regimen had failed. Intervention: consecutive rescue therapies were prescribed empirically according to the best scientific evidence. Helicobacter pylori eradication was defined by a negative 13 C-ureabreathtest.Results: A total of 1200 subjects were included. Eleven different therapies were used during the study period, being the seven most common: proton pump inhibitor (PPI)-levofloxacin (LEV)-amoxicillin (AMO); PPI-bismuth(BIS)-LEV-AMO; PPI-moxifloxacin-AMO; ranitidine bismuth citrate-tetracycline-metronidazole; classical BIS (BIS)-containing quadruple therapy; PPI-Pylera ® and PPI-rifabutin (RIF)-AMO. The effectivenessofthesecond-,third-,fourth-andfifth-linerescuetherapieswas77%, 71%,60%and58%,respectively.Thecumulativeeffectivenessafterfiveconsecutive therapieswas99.8%.Thethreemosteffectivesecond-andthird-linetherapieswere: PPI-Pylera ® (96%and82%,respectively),classicalBIS-containingquadrupletherapy (92%and89%)andPPI-BIS-LEV-AMO(88%and84%). Conclusions: Helicobacter pylori eradication can be achieved virtually in all cases by the administration of several consecutive empirical therapies. The most effective second-linestrategyistheadministrationofaBIS-containingquadrupletherapy(either classical, Pylera ® or with LEV-AMO). The most effective third-line strategy is theadministrationofanotpreviouslyusedBIS-containingquadrupletherapy.Agood alternativeasafourth-linetherapyistheadministrationofPPI-RIF-AMO-BIS.

show abstract

Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori—Synthesizing the Guidelines

Bjorkman

Steenblik

2017

Curr Treat Options Gastro

View full text Add to dashboard Cite

Purpose of review Three guidelines on Helicobacter pylori have been published recently with recommendations that differ from past guidelines. In this review, we summarize the Toronto consensus statement, the Maastricht V/Florence consensus report and the American College of Gastroenterology guidelines on H. pylori, comparing and contrasting the recommendations. We also provide a proposed approach integrating the information from all three guidelines. Findings Increasing antibiotic resistance has decreased the effectiveness of past treatment regimens for H. pylori. The recommended treatment approach should be based on local and individual antibiotic resistance patterns. Empiric first-line therapy should be a 14-day course of bismuth- or antibiotic-based quadruple therapy. Clarithromycin triple therapy is not recommended unless the local clarithromycin resistance rate is less than 15%. Second-line therapy should be influenced by the failed first-line therapy. Quadruple bismuth-based therapy or levofloxacin-based therapy are suggested regimens. Testing for antibiotic resistance is recommended after multiple failed treatments. Summary Therapy of H. pylori should be based on the knowledge of local antibiotic resistance patterns. Unfortunately, these are often not available. Additional efforts are needed to define local antibiotic resistance to allow susceptibility-based treatment. In the meantime, 14-day quadruple therapy with bismuth or concomitant antibiotics is the recommended as an empiric first-line treatment approach.

show abstract

IV Spanish Consensus Conference on Helicobacter pylori infection treatment

Cited by 54 publications

References 175 publications

Helicobacter pylori and Hematologic Diseases

Helicobacter pylori and Hematologic Diseases

Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients

Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori—Synthesizing the Guidelines

Contact Info

Product

Resources

About